Company Profile
Northwest Biotherapeutics Stock Price, News & Catalysts
- Ticker:
- NWBO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.15 USD (-1.88%)
Close
Last updated: October 6, 2026
—
Market cap
Why the stock is moving
As of Oct 6, 2026, NWBO closed down 1.88% at $0.1460. No new same-company headline was identified in the current news window.
Company overview
Personalized Cancer Vaccine Company
Northwest Biotherapeutics develops dendritic-cell therapies intended to activate a patient's immune system against a broad set of tumor antigens. Its platform uses tumor material from each patient to create an individualized vaccine.
DCVax-L for Resectable Tumors
DCVax-L is manufactured from a patient's dendritic cells and lysate from the surgically removed tumor. The lead development program has focused on glioblastoma, supported by a completed international Phase 3 study.
DCVax-Direct for Inoperable Tumors
DCVax-Direct is designed for direct injection into tumors that cannot be surgically removed. The approach aims to expose dendritic cells to tumor antigens inside the body and has completed early clinical testing across solid tumors.
Manufacturing Infrastructure
The company and its partners operate manufacturing capabilities in the United Kingdom, including the Sawston facility. Northwest Bio is also developing Flaskworks automation to reduce manual processing and improve the scalability and consistency of individualized manufacturing.
Platform and Combination Potential
Because each vaccine contains a broad range of patient-specific antigens, the platform may be used across multiple solid tumors. The company has also explored combinations with checkpoint inhibitors and other immune therapies.
Advent BioServices
Advent BioServices provides manufacturing, process development, controlled storage, and distribution services at the Sawston site. Ownership of this operation gives Northwest Bio more direct control over production and can support third-party service activity.
Future catalysts
- MHRA regulatory decision on the UK marketing authorization application for DCVax-L in glioblastoma.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Northwest Biotherapeutics (NWBO)?
Northwest Biotherapeutics (NWBO) most recently closed at 0.15 USD, a -1.88% move versus the previous session.
What does Northwest Biotherapeutics do?
Personalized Cancer Vaccine Company Northwest Biotherapeutics develops dendritic-cell therapies intended to activate a patient's immune system against a broad set of tumor antigens. Its platform uses tumor material from each patient to create an individualized vaccine. DCVax-L for Resectable Tumors DCVax-L is manufactured from a patient's dendritic cells...
On which exchange is NWBO stock listed?
Northwest Biotherapeutics (NWBO) is associated with NASDAQ, United States, Biopharma.
What is Personalized?
Personalized Cancer Vaccine Company Northwest Biotherapeutics develops dendritic-cell therapies intended to activate a patient's immune system against a broad set of tumor antigens.
Which conditions is Northwest Biotherapeutics targeting with Personalized?
Northwest Biotherapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Northwest Biotherapeutics describe recent progress with Personalized?
MHRA regulatory decision on the UK marketing authorization application for DCVax-L in glioblastoma.
What is Cancer?
Personalized Cancer Vaccine Company Northwest Biotherapeutics develops dendritic-cell therapies intended to activate a patient's immune system against a broad set of tumor antigens.
What should investors watch for with Cancer?
MHRA regulatory decision on the UK marketing authorization application for DCVax-L in glioblastoma.